During the last session, Vir Biotechnology Inc (NASDAQ:VIR)’s traded shares were 1.98 million, with the beta value of the company hitting 0.65. At the end of the trading day, the stock’s price was $11.20, reflecting an intraday gain of 6.36% or $0.67. The 52-week high for the VIR share is $14.45, that puts it down -29.02 from that peak though still a striking 41.43% gain since the share price plummeted to a 52-week low of $6.56. The company’s market capitalization is $1.54B, and the average intraday trading volume over the past 10 days was 6.15 million shares, and the average trade volume was 2.18 million shares over the past three months.
Vir Biotechnology Inc (VIR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.56. VIR has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.87.
Vir Biotechnology Inc (NASDAQ:VIR) trade information
Vir Biotechnology Inc (VIR) registered a 6.36% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.36% in intraday trading to $11.20, hitting a weekly high. The stock’s 5-day price performance is 6.67%, and it has moved by 51.97% in 30 days. Based on these gigs, the overall price performance for the year is 16.67%. The short interest in Vir Biotechnology Inc (NASDAQ:VIR) is 6.55 million shares and it means that shorts have 4.51 day(s) to cover.
The consensus price target of analysts on Wall Street is $24, which implies an increase of 53.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $28 respectively. As a result, VIR is trading at a discount of -150.0% off the target high and -78.57% off the low.
Vir Biotechnology Inc (VIR) estimates and forecasts
Statistics show that Vir Biotechnology Inc has underperformed its competitors in share price, compared to the industry in which it operates. Vir Biotechnology Inc (VIR) shares have gone up 9.80% during the last six months, with a year-to-date growth rate less than the industry average at 14.60% against 16.50. In the rating firms’ projections, revenue will decrease -12.77% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.37M as predicted by 5 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 13.66M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 16.79M and 56.38M respectively. In this case, analysts expect current quarter sales to shrink by -44.19% and then drop by -75.77% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -34.12%. While earnings are projected to return 15.42% in 2025.
VIR Dividends
Vir Biotechnology Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders
Vir Biotechnology Inc insiders own 11.90% of total outstanding shares while institutional holders control 74.53%, with the float percentage being 84.60%. SB INVESTMENT ADVISERS (UK) LTD is the largest shareholder of the company, while 289.0 institutions own stock in it. As of 2024-06-30, the company held over 16.68 million shares (or 12.3329% of all shares), a total value of $148.49 million in shares.
The next largest institutional holding, with 16.43 million shares, is of BLACKROCK INC.’s that is approximately 12.1482% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $146.26 million.
Also, the Mutual Funds coming in first place with the largest holdings of Vir Biotechnology Inc (VIR) shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . Data provided on Oct 31, 2024 indicates that iShares Core S&P Smallcap ETF owns about 5.82 shares. This amounts to just over 4.23 percent of the company’s overall shares, with a $65.18 million market value. The same data shows that the other fund manager holds slightly less at 3.46, or about 2.51% of the stock, which is worth about $38.77 million.
